Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate efficacy and safety of targeted precision therapy in
patients with refractory tumor, including rare tumor without standard recommended treatment
and common tumor after multiple line of therapy.